Given these findings, the evolution of small-compound tyrosine kinase inhibitors that target the ATP binding site of VEGFR-2 to inhibit angiogenesis in tumor cells is a considerable strategy for developing safe and selective anti-cancer drugs. The gene discussed is KDR; the disease is cancer.